SCHEMBL7019308

SCHEMBL7019308

Cn1c(=O)n(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cc(C(=O)O)ccc21

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.59
SLC22A8 Q8TCC7 1/20 0.59
MTHFD2 P13995 1/20 0.54
SRC P12931 1/20 0.48
PRKACA P17612 1/20 0.48
PRKACG P22612 1/20 0.48
PRKACB P22694 1/20 0.48
PARG Q86W56 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
CCR2 P41597 9/20 0.47
HDAC1 Q13547 1/20 0.47
ABCB11 O95342 3/20 0.46
LMNA P02545 1/20 0.45
STAT6 P42226 1/20 0.45
HIF1A Q16665 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7012164 0.90 MMP13 (0.56) MMP13SLC22A8MTHFD2PARGCCR2
SCHEMBL6253605 0.90 MMP13 (0.62) MMP13SLC22A8PARGHDAC1
SCHEMBL7100616 0.87 MMP13 (0.62) MMP13SLC22A8PARGSMN1; SMN2HDAC1
SCHEMBL6241073 0.87 MMP13 (0.71) MMP13SLC22A8PARGSMN1; SMN2HDAC1
SCHEMBL6238935 0.86 MMP13 (0.61) MMP13SLC22A8PARGHDAC1
SCHEMBL7095893 0.86 MMP13 (0.61) MMP13SLC22A8MTHFD2PARGSMN1; SMN2
SCHEMBL6256249 0.86 MMP13 (0.61) MMP13SLC22A8PARGHDAC1LMNA
SCHEMBL7012936 0.85 MMP13 (0.61) MMP13SLC22A8PARGSMN1; SMN2CCR2
SCHEMBL6256616 0.84 MMP13 (0.59) MMP13SLC22A8PARGCCR2HDAC1
SCHEMBL6466057 0.84 MMP13 (0.57) MMP13SLC22A8PARGHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MMP13 1/4885SLC22A8 315/4885MTHFD2 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.